Prosecution Insights
Last updated: April 19, 2026
Application No. 18/284,411

CITRATE-CONTAINING COMPOSITION, PRODUCTION METHOD AND DRY METHOD THEREFOR, AND TABLET CONTAINING SAID COMPOSITION

Non-Final OA §112
Filed
Sep 27, 2023
Examiner
SHIAO, REI TSANG
Art Unit
1691
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Nippon Chemiphar Co., Ltd.
OA Round
1 (Non-Final)
80%
Grant Probability
Favorable
1-2
OA Rounds
2y 3m
To Grant
45%
With Interview

Examiner Intelligence

Grants 80% — above average
80%
Career Allow Rate
1612 granted / 2019 resolved
+19.8% vs TC avg
Minimal -35% lift
Without
With
+-35.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
53 currently pending
Career history
2072
Total Applications
across all art units

Statute-Specific Performance

§101
0.7%
-39.3% vs TC avg
§103
29.1%
-10.9% vs TC avg
§102
8.1%
-31.9% vs TC avg
§112
29.6%
-10.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 2019 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Priority and Status of Claims 1. This application is a 371 of PCT/JP2022/015012 03/28/2022, which claims benefit of the foreign applications: JAPAN JP2021-055436 03/29/2021. 2. Claims 1-31 are pending in the application. Claim Rejections - 35 USC § 112 3. The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. Claims 1-31 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112, first paragraph (pre- AIA ), because the specification does not reasonably provide enablement of the instant “salt of citric acid” without limitation (i.e., no named salts). The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make the invention commensurate in scope with these claims. ln In re Wands, 8 USPQ2d 1400 (1988), factors to be considered in determining whether a disclosure meets the enablement requirement of 35 U.S.C. 112, first paragraph, have been described. They are: 1. the nature of the invention, 2. the state of the prior art, 3. the predictability or Iack thereof in the art, 4. the amount of direction or guidance present, 5. the presence or absence of working examples, 6. the breadth of the claims, 7. the quantity of experimentation needed, and 8. the level of the skill in the art. In the instant case: The nature of the invention The nature of the invention is a method of use using “salt of citric acid” without limitation (i.e., no named salts), see claim 1, 20, 27 and 31. The state of the prior art and the predictability or Iack thereof in the art The state of the prior art is Wang et al. CAS: 163: 399070, 2015, it discloses a compound sodium citrate dihydrate. The amount of direction or guidance present and the presence or absence of working examples The only direction or guidance present in the instant specification is the description of a number of “salt of citric acid” on pages 40-46 of the specification. There is no data present in the instant specification for the “salt of citric acid” without limitation (i.e., no named salts). The breadth of the claims The instant breadth of the rejected claims is broader than the disclosure, specifically, the instant “salt of citric acid” are without limitation (i.e., no named salts). The quantity or experimentation needed and the Ievel of skill in the art While the level of the skill in the chemical arts is high, it would require undue experimentation of one of ordinary skill in the art to resolve any “salt of citric acid” without limitation. There is no guidance or working examples present for constitutional any “LSD1inhibitor” without limitation for the instant invention. Incorporation of the limitation of “salt of citric acid r” supported by specification (i.e., claim 4) into claim 1, 20, 27 and 31 would overcome this rejection. 4. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION-The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. Claim 31 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. Claim 31, lines 2-4, recites the limitation “a total content of said composition does not exceed 100% by mass with respect to a total mass of solid content of said composition” is ambiguous and indefinite. It is unclear what the scope or amount of the solid content of composition. Clarification is required. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to REI TSANG SHIAO whose telephone number is (571)272-0707. The examiner can normally be reached on 8:30 am-5:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor can be reached on 571-272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /REI TSANG SHIAO/ Rei-tsang Shiao, Ph.D.Primary Examiner, Art Unit 1691 January 26, 2026
Read full office action

Prosecution Timeline

Sep 27, 2023
Application Filed
Jan 26, 2026
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599580
COMPOSITION COMPRISING A LIPID COMPOUND, A TRIGLYCERIDE, AND A SURFACTANT, AND METHODS OF USING THE SAME
2y 5m to grant Granted Apr 14, 2026
Patent 12600719
SALT INDUCIBLE KINASE INHIBITORS
2y 5m to grant Granted Apr 14, 2026
Patent 12599579
COMPOSITIONS AND COMPOUNDS CONTAINNG KETONE BODIES AND/OR KETONE BODY PRECURSORS AND ONE OR MORE AMINO ACIDS
2y 5m to grant Granted Apr 14, 2026
Patent 12595556
MOLYBDENUM IMIDO ALKYL/ALLYL COMPLEXES FOR DEPOSITION OF MOLYBDENUM-CONTAINING FILMS
2y 5m to grant Granted Apr 07, 2026
Patent 12594254
INTRANASAL ADMINISTRATION OF N-ACETYLCYSTEINE AND USES THEREOF
2y 5m to grant Granted Apr 07, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
80%
Grant Probability
45%
With Interview (-35.0%)
2y 3m
Median Time to Grant
Low
PTA Risk
Based on 2019 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month